Open AccessLenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma
Author(s) -
Shakthi Bhaskar,
Brooj Abro,
Tyler J. Fraum,
Neha MehtaShah
Publication year - 2020
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2020-235578
Subject(s) - lenalidomide , medicine , anaplastic lymphoma kinase , lymphoma , multiple myeloma , oncology , aggressive lymphoma , anaplastic large cell lymphoma , large cell lymphoma , cancer research , rituximab , malignant pleural effusion , lung cancer
Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodulator that has shown safety and efficacy in multiple myeloma and is also approved for use in several types of lymphoma. In the case described here, the patient had a significant partial response to lenalidomide, which has not previously been described in this type of lymphoma. Given how aggressive and difficult to treat ALK+ LBCL is, further research is warranted to more completely elucidate the mechanism of action of lenalidomide in ALK+ LBCL and its role in treatment.